You are viewing a preview of...

Small RNA Therapeutics for Prostate Cancer

Targeting the androgen network without developing therapeutic resistance in prostate cancer

Background

Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Therapies for advanced PCa are mainly directed at blocking the activity of the androgen receptor (AR), which is essential for PCa cell growth. However, current strategies for targeting AR are problematic due to the resulting therapeutic resistance and development of a currently incurable and aggressive form of PCa. Identifying new ways to target AR signaling is essential for developing novel effective PCa treatments while avoiding triggering resistance.

Log in or create a free account to continue reading